Bristol-Myers Gets FDA Acceptance of Review for Subcutaneous Opdivo Formulation
By Colin Kellaher
Bristol Myers Squibb on Monday said the Food and Drug Administration has accepted its application seeking approval of an subcutaneous formulation of its blockbuster cancer drug Opdivo.
The Princeton, N.J., biopharmaceutical company said the application covers Opdivo co-formulated with Halozyme's Enhanze drug-delivery technology across all previously approved adult, solid-tumor Opdivo indications as monotherapy, monotherapy maintenance following completion of Opdivo plus Yervoy combination therapy, or in combination with chemotherapy or cabozantinib.
Opdivo, which harnesses the body's own immune system to fight cancer and generated more than $9 billion in revenue last year, is currently administered intravenously.
Bristol Myers said the FDA has set a target action date for the application of Feb. 28, 2025, adding that an FDA green light would make Opdivo the first and only subcutaneously administered PD-1 inhibitor.
Bristol-Myers and San Diego biopharmaceutical company Halozyme in 2017 inked a collaboration and license agreement to develop subcutaneously administered Bristol-Myers medicines using Halozyme's Enhanze technology, a recombinant human hyaluronidase solution used to facilitate the subcutaneous delivery of injected drugs and fluids.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
May 06, 2024 07:50 ET (11:50 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s Happening in the Markets This Week
-
Worst-Performing Stock ETFs of the Quarter
-
Q3 in Review and Q4 2024 Market Outlook
-
Top-Performing Stock ETFs of the Quarter
-
September Jobs Report Forecasts Show Moderate Hiring Gains
-
Port Strike a Headache for Shippers but a Potential Tailwind for Certain US Transport Stocks
-
13 Charts on Q3′s Roller-Coaster Rally for Stocks and Bonds
-
5 Stocks to Buy Instead of Overpriced US Equities
-
Consumer Defensives: Despite Angst, Thirsty Investors Have Names to Pursue
-
Industrials: Many Stocks Overvalued After Q3 Outperformance
-
Basic Materials: Despite Index Rise, We See Multiple Long-Term Opportunities
-
What the Election Could Mean for Big Tech Stocks
-
3 Lessons From Recent Stock Market Drama
-
Consumer Cyclicals: Even Amid Moderating Consumer Spending, We See Discounts
-
Healthcare: Valuations Look Fair Overall, With Select Industries Still Undervalued
-
Utilities: Falling Interest Rates, Growth Outlook Boosting Stocks